Kalvista kiest toch niet voor Pharming als verkoopkanaal.
De genoemde bedragen zijn wel van andere koek dan de kleine leniolisib deal.
DRI Healthcare Trust secures royalty rights in sebetralstat
Kalvista's on-demand HAE treatment up for approval in several countries
DRI Healthcare Trust, an investment firm, has acquired rights to royalty interest in sebetralstat, an on-demand treatment for hereditary angioedema (HAE) that’s being considered for approval in several countries, including the U.S.
For Kalvista Pharmaceuticals, the therapy’s developer, the deal could be worth more than $175 million, according to a DRI press release.
...
With this transaction, DRI will be entitled to 5% of all net sales of sebetralstat up to $500 million. The trust also would get 1.1% of net sales from $500 million up to and including $750 million, and 0.25% on net sales beyond $750 million.